Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Promitil with FOLFOX in GI Malignancies
NCT04729205Phase 1Terminated
- Sponsor
- LipoMedix
- Start
- Jan 2021
- Primary completion
- Sep 2023
- Modality
- Lipid-based Nanoparticles, Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of Mitomycin-c lipidic prodrug in gastrointestinal cancer (2 arms), sponsored by LipoMedix. Primary endpoints: Incidence of Treatment-Emergent Adverse Events at 12 weeks, Dose limiting toxicity at 8 weeks and 1 more. Started Jan 2021; status: terminated.
02
Drugs
Mitomycin-c lipidic prodrug
03
Conditions
gastrointestinal cancer
Beyond the preview
Go deeper on NCT04729205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04729205.